Therapeutic use of the high-density lipoprotein protein and peptides

Bibliography

• KANNEL WB, NEATON JD, WENTWORTH D et al.: Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT (Multiple Risk Factor Intervention Trial). Am. Heart J. (1986) 112:825-836.
   PubMed Web of Science ®Google Scholar
• CASTELLI WP, GARRISON RJ, WILSON PW, ABBOTT RD, KALOUSDIAN S, KANNEL WB: Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. J. Am. Med. Assoc. (1986) 256:2835-2838.
   PubMed Web of Science ®Google Scholar
• HOPKINS PN, WU LL, HUNT SC, BRINTON EA: Plasma triglycerides and Type III hyperlipidemia are independently associated with premature familial coronary artery disease. J. Am. Coll. Cardiol. (2005) 45:1003-1012.
   PubMed Web of Science ®Google Scholar
• MALDONADO EN, CASANAVE EB, AVELDANO MI: Major plasma lipids and fatty acids in four HDL mammals. Comp. Biochem. Physiol. A. Mol. Integr. Physiol. (2002) 132:297-303.
   PubMed Web of Science ®Google Scholar
• CALABRESI L, GOMARASCHI M, FRANCESCHINI G: Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler. Thromb. Vasc. Biol. (2003) 23:1724-1731.
   PubMed Web of Science ®Google Scholar
• STEIN O, STEIN Y: Atheroprotective mechanisms of HDL. Atherosclerosis (1999) 144:285-301.
   PubMed Web of Science ®Google Scholar
• SPADY DK: Reverse cholesterol transport and atherosclerosis regression. Circulation (1999) 100:576-578.
   PubMed Web of Science ®Google Scholar
• FRANCESCHINI G, MADERNA P, SIRTORI CR: Reverse cholesterol transport: physiology and pharmacology. Atherosclerosis (1991) 88:99-107.
   PubMed Web of Science ®Google Scholar
• ROTHBLAT GH, DE LA LLERA-MOYA M, ATGER V, KELLNER-WEIBEL G, WILLIAMS DL, PHILLIPS MC: Cell cholesterol efflux: integration of old and new observations provides new insight. J. Lipid Res. (1999) 40:781-796.
   PubMed Web of Science ®Google Scholar
• NAQVI TZ, SHAH PK, IVEY PA et al.: Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation. Am. J. Cardiol. (1999) 84:1011-1017.
   PubMed Web of Science ®Google Scholar
• SAKU K, AHMAD M, GLAS-GREENWALT P, KASHYAP ML: Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man. Thromb. Res. (1985) 39:1-8.
   PubMed Web of Science ®Google Scholar
• BARTER PJ: Inhibition of endothelial cell adhesion molecule expression by high density lipoproteins. Clin. Exp. Pharmacol. Physiol. (1997) 24:286-287.
   PubMed Web of Science ®Google Scholar
• COCKERILL GW, RYE KA, GAMBLE JR, VADAS MA, BARTER PJ: High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler. Thromb. Vasc. Biol. (1995) 15:1987-1994.
   PubMed Web of Science ®Google Scholar
• CALABRESI L, FRANCESCHINI G, SIRTORI CR et al.: Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins. Biochem. Biophys. Res. Commun. (1997) 238:61-65.
   PubMed Web of Science ®Google Scholar
• RUBINS HB, ROBINS SJ, COLLINS D et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. (1999) 341:410-418.
   PubMed Web of Science ®Google Scholar
• RUBINS HB, ROBINS SJ: Conclusions from the VA-HIT study. Am. J. Cardiol. (2000) 86:543-544.
   PubMed Web of Science ®Google Scholar
• BIRJMOHUN RS, HUTTEN BA, KASTELEIN JJP et al.: Efficacy and safety of high–density lipoprotein cholesterol-increasing compounds. A meta-analysis of randomized controlled trials. J. Am. Coll. Cardiol. (2005) 45:185-197.
   PubMed Web of Science ®Google Scholar
• STEINER G, HAMSTEN A, HOSKING J et al.: Effect of fenofibrate on progression of coronary-artery disease in Type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet (2001) 357:905-910.
   PubMed Web of Science ®Google Scholar
• BROWN BG, ZHAO X-Q, CHAIT A et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. (2001) 345:1583-1592.
   PubMed Web of Science ®Google Scholar
• TAYLOR AJ, SULLENBERGER LE, LEE HJ, LEE JK, GRACE KA: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation (2004) 110:3512-3517.
   PubMed Web of Science ®Google Scholar
• WHITNEY EJ, KRASUSKI RA, PERSONIUS BE et al.: A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann. Intern. Med. (2005) 142:95-104.
   PubMed Web of Science ®Google Scholar
• FRANCESCHINI G, SIRTORI CR, CAPURSO A, WEISGRABER KH, MAHLEY RW: A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an italian family. J. Clin. Invest. (1980) 66:892-900.
   PubMed Web of Science ®Google Scholar
• WEISGRABER KH, RALL SC Jr, BERSOT TP, MAHLEY RW, FRANCESCHINI G, SIRTORI CR: Apolipoprotein AIMilano. Detection of normal AI in affected subjects and evidence for a cysteine for arginine substitution in the variant AI. J. Biol. Chem. (1983) 258:2508-2513.
   PubMed Web of Science ®Google Scholar
• FRANCESCHINI G, SIRTORI CR, BOSISIO E et al.: Relationship of the phenotypic expression of the A-IMilano apoprotein with plasma lipid and lipoprotein patterns. Atherosclerosis (1985) 58:159-174.
   PubMed Web of Science ®Google Scholar
• FRICK MH, ELO O, HAAPA K et al.: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. (1987) 317:1237-1245.
   PubMed Web of Science ®Google Scholar
• CULLEN P, SCHULTE H, ASSMANN G: The Munster Heart Study (PROCAM): total mortality in middle-aged men is increased at low total and LDL cholesterol concentrations in smokers but not in nonsmokers. Circulation (1997) 96:2128-2136.
   PubMed Web of Science ®Google Scholar
• SIRTORI CR, CALABRESI L, FRANCESCHINI G et al.: Cardiovascular status of carriers of the apolipoprotein A-IMilano mutant: the Limone sul Garda study. Circulation (2001) 103:1949-1954.
   PubMed Web of Science ®Google Scholar
• FRANCESCHINI G, CALABRESI L, CHIESA G et al.: Increased cholesterol efflux potential of sera from ApoA-IMilano carriers and transgenic mice. Arterioscler. Thromb. Vasc. Biol. (1999) 19:1257-1262.
   PubMed Web of Science ®Google Scholar
• CALABRESI L, CANAVESI M, BERNINI F, FRANCESCHINI G: Cell cholesterol efflux to reconstituted high-density lipoproteins containing the apolipoprotein A-IMilano dimer. Biochemistry (1999) 38:16307-16314.
   PubMed Web of Science ®Google Scholar
• BIELICKI JK, ODA MN: Apolipoprotein A-IMilano and apolipoprotein A-IParis exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I. Biochemistry (2002) 41:2089-2096.
   PubMed Web of Science ®Google Scholar
• JIA Z, NATARAJAN P, FORTE TM, BIELICKI JK: Thiol-bearing synthetic peptides retain the antioxidant activity of apolipoproteinA-IMilano. Biochem. Biophys. Res. Commun. (2002) 297:206-213.
   PubMed Web of Science ®Google Scholar
• ROMA P, GREGG RE, MENG MS et al.: In vivo metabolism of a mutant form of apolipoprotein A-I, apo A-IMilano, associated with familial hypoalphalipoproteinemia. J. Clin. Invest. (1993) 91:1445-1452.
   PubMed Web of Science ®Google Scholar
• CALABRESI L, VECCHIO G, LONGHI R et al.: Molecular characterization of native and recombinant apolipoprotein A-IMilano dimer. The introduction of an interchain disulfide bridge remarkably alters the physicochemical properties of apolipoprotein A-I. J. Biol. Chem. (1994) 269:32168-32174.
   PubMed Web of Science ®Google Scholar
• SCHMIDT HH, REMALEY AT, STONIK JA et al.: Carboxyl-terminal domain truncation alters apolipoprotein A-I in vivo catabolism. J. Biol. Chem. (1995) 270:5469-5475.
   PubMed Web of Science ®Google Scholar
• HOLVOET P, ZHAO Z, VANLOO B et al.: Phospholipid binding and lecithin-cholesterol acyltransferase activation properties of apolipoprotein A-I mutants. Biochemistry (1995) 34:13334-13342.
   PubMed Web of Science ®Google Scholar
• DAVIDSON WS, HAZLETT T, MANTULIN WW, JONAS A: The role of apolipoprotein AI domains in lipid binding. Proc. Natl. Acad. Sci. USA (1996) 93:13605-13610.
   PubMed Web of Science ®Google Scholar
• SORCI TM, KEARNS MW, LEE JP: Apolipoprotein A-I domains involved in lecithin-cholesterol a cyltransferase activation. Structure–function relationships. J. Biol. Chem. (1993) 268:21403-21409.
   PubMed Web of Science ®Google Scholar
• BADIMON JJ, BADIMON L, FUSTER V: Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J. Clin. Invest. (1990) 85:1234-1241.
   PubMed Web of Science ®Google Scholar
• SHAH PK, NILSSON J, KAUL S et al.: Effects of recombinant apolipoprotein A-IMilano on aortic atherosclerosis in apolipoportein E-deficient mice. Circulation (1998) 97:780-785.
   PubMed Web of Science ®Google Scholar
• SHAH PK, YANO J, REYES O et al.: High-dose recombinant apolipoprotein A-IMilano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice. Circulation (2001) 103:3047-3050.
   PubMed Web of Science ®Google Scholar
• CHIESA G, DI MARIO C, COLOMBO N et al.: Development of a lipid-rich, soft plaque in rabbits, monitored by histology and intravascular ultrasound. Atherosclerosis (2001) 156:277-287.
   PubMed Web of Science ®Google Scholar
• CHIESA G, MONTEGGIA E, MARCHESI M et al.: Recombinant apolipoprotein A-IMilano infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ. Res. (2002) 90:974-980.
   PubMed Web of Science ®Google Scholar
• NICHOLLS SJ, CUTRI B, WORTHLEY SG et al.: Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits. Arterioscler. Thromb. Vasc. Biol. (2005) 25:2416-2421.
   PubMed Web of Science ®Google Scholar
• STONE BG, SCHREIBER D, ALLEMAN LD, HO CY: Hepatic metabolism and secretion of a cholesterol-enriched lipoprotein fraction. J. Lipid. Res. (1987) 28:162-172.
   PubMed Web of Science ®Google Scholar
• BARTER PJ, BREWER HB Jr, CHAPMAN MJ, HENNEKENS CH, RADER DJ, TALL AR: Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler. Thromb. Vasc. Biol. (2003) 23:160-167.
   PubMed Web of Science ®Google Scholar
• AMELI S, HULTGARDH-NILSSON A, CERCEK B et al.: Recombinant apolipoprotein A-IMilano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation (1994) 90:1935-1941.
   PubMed Web of Science ®Google Scholar
• SOMA MR, DONETTI E, PAROLINI C, SIRTORI CR, FUMAGALLI R, FRANCESCHINI G: Recombinant apolipoprotein A-IMilano dimer inhibits carotid intimal thickening induced by perivascular manipulation in rabbits. Circ. Res. (1995) 76:405-411.
   PubMed Web of Science ®Google Scholar
• NILSSON J, DAHLGREN B, ARES M et al.: Lipoprotein-like phospholipid particles inhibit the smooth muscle cell cytotoxicity of lysophosphatidylcholine and platelet-activating factor. Arterioscler. Thromb. Vasc. Biol. (1998) 18:13-19.
   PubMed Web of Science ®Google Scholar
• SIRTORI CR, MARCHESI M: High density lipoprotein administration: a new therapeutic modality for the treatment of cardiovascular diseases. Curr. Med. Chem. (2005) 5:321-333.
   Google Scholar
• KAUL S, RUKSHIN V, SANTOS R et al.: Intramural delivery of recombinant apolipoprotein A-IMilano/phospholipid complex (ETC-216) inhibits in-stent stenosis in porcine coronary arteries. Circulation (2003) 107:2551-2554.
   PubMed Web of Science ®Google Scholar
• DIMAYUGA P, ZHU J, OGUCHI S et al.: Reconstitued HDL containing human apolipoprotein A-I reduces VCAM-1 expression and neointima formation following periadventitial cuff-induced carotid injury in apoE null mice. Biochem. Biophys. Res. Commun. (1999) 264:465-468.
   PubMed Web of Science ®Google Scholar
• KAUL S, COIN B, HEDAYITI A et al.: Rapid reversal of endothelial dysfunction in hypercholesterolemic apolipoprotein E-null mice by recombinant apolipoprotein A-IMilano-phospholipid complex. J. Am. Coll. Cardiol. (2004) 44:1311-1319.
   PubMed Web of Science ®Google Scholar
• LI D, WENG S, YANG B et al.: Inhibition of arterial thrombus formation by ApoA-IMilano. Arterioscler. Thromb. Vasc. Biol. (1999) 19:378-383.
   PubMed Web of Science ®Google Scholar
• CHEN LY, MEHTA P, MEHTA JL: Oxidized LDL decreases L-arginine uptake and nitric oxide synthase protein expression in human platelets: relevance of the effect of oxidized LDL on platelet function. Circulation (1996) 93:1740-1746.
   PubMed Web of Science ®Google Scholar
• CALABRESI L, ROSSONI G, GOMARASCHI M, SISTO F, BERTI F, FRANCESCHINI G: High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-α content and enhancing prostaglandin release. Circ. Res. (2003) 92:330-337.
   PubMed Web of Science ®Google Scholar
• ROSSONI G, GOMARASCHI M, BERTI F, SIRTORI CR, FRANCESCHINI G, CALABRESI L: Synthetic high-density lipoproteins exert cardioprotective effects in myocardial ischemia/reperfusion injury. J. Pharmacol. Exp. Ther. (2004) 308:79-84.
   PubMed Web of Science ®Google Scholar
• MARCHESI M, BOOTH EA, DAVIS T, BISGAIER CL, LUCCHESI BR: Apolipoprotein A-IMilano and 1-palmitoyl-2-oleoyl phosphatidylcholine complex (ETC-216) protects the in vivo rabbit heart from regional ischemia-reperfusion injury. J. Pharmacol. Exp. Ther. (2004) 311:1023-1031.
   PubMed Web of Science ®Google Scholar
• PARK JL, LUCCHESI BR: Mechanisms of myocardial reperfusion injury. Ann. Thorac. Surg. (1999) 68:1905-1912.
   PubMed Web of Science ®Google Scholar
• ZWEIER JL, FLAHERTY JT, WEISFELDT ML: Direct measurement of free radical generation following reperfusion of ischemic myocardium. Proc. Natl. Acad. Sci. USA (1987) 84:1404-1407.
   PubMed Web of Science ®Google Scholar
• TRITTO I, DUILIO C, SANTORO G: A short burst of oxygen radicals at reflow induces sustained release of oxidized glutathione from postischemic hearts. Free Radic. Biol. Med. (1998) 24:290-297.
   PubMed Web of Science ®Google Scholar
• AMBROSIO G, FLAHERTY JT, DUILIO C: Oxygen radicals generated at reflow induce peroxidation of membrane lipids in reperfused hearts. J. Clin. Invest. (1991) 87:2056-2066.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZA WV, KLIMUK SK, PRITCHARD PH, HOPE MJ: Cholesterol mobilization and regression of atheroma in cholesterol-fed rabbits induced by large unilamellar vesicles. Biochim. Biophys. Acta (1998) 1368:306-320.
   PubMed Web of Science ®Google Scholar
• NAVAB M, ANANTHARAMAIAH GM, JAMA S et al.: Oral administration of an apoA-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation (2002) 105:290-292.
   PubMed Web of Science ®Google Scholar
• NAVAB M, ANANTHARAMAIAH GM, REDDY ST et al.: Oral D-4F causes formation of pre-b high density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation (2004) 109:3215-3220.
   PubMed Web of Science ®Google Scholar
• NAVAB M, ANANTHARAMAIAH GM, REDDY ST et al.: An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol. (2005) 25:1932-1937.
   PubMed Web of Science ®Google Scholar
• VAN LENTEN BJ, WAGNER AC, NAVAB M et al.: D-4F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes. Circulation (2004) 110:3252-3258.
   PubMed Web of Science ®Google Scholar
• LI X, CHYU K-Y, FARIA NETO JR et al.: Differential effects of apolipoprotein A-I mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Circulation (2004) 110:1701-1705.
   PubMed Web of Science ®Google Scholar
• LERCH PG, FORTSCH V, HODLER G, BOLLI R: Production and characterization of a reconstituted high density lipoprotein for therapeutic applications. Vox Sang. (1996) 71:155-164.
   PubMed Web of Science ®Google Scholar
• CARLSON LA: Effect of a single infusion of recombinant human proapolipoprotein A-I liposomes (synthetic HDL) on plasma lipoproteins in patients with low high density lipoprotein cholesterol. Nutr. Metab. Cardiovasc. Dis. (1995) 5:85-91.
   Web of Science ®Google Scholar
• ERIKSSON M, CARLSON LA, MIETTINEN TA, ANGELIN B: Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I: potential reverse cholesterol transport in humans. Circulation (1999) 100:594-598.
   PubMed Web of Science ®Google Scholar
• NANJEE MN, CROUSE JR, KING JM et al.: Effects of intravenous infusion of lipid-free apo A-I in humans. Arterioscler. Thromb. Vasc. Biol. (1996) 16:1203-1214.
   PubMed Web of Science ®Google Scholar
• NANJEE MN, COOKE CJ, GARVIN R et al.: Intravenous apoA-I/lecithin discs increase pre-β-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. J. Lipid Res. (2001) 42:1586-1593.
   PubMed Web of Science ®Google Scholar
• NANJEE MN, DORAN JE, LERCH PG, MILLER NE: Acute effcts of intravenous infusion of ApoA-I/phosphatidylcholine discs on plasma lipoproteins in humans. Arterioscler. Thromb. Vasc. Biol. (1999) 19:979-989.
   PubMed Web of Science ®Google Scholar
• SPIEKER LE, SUDANO I, HURLIMANN D et al.: High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation (2002) 105:1399-1402.
   PubMed Web of Science ®Google Scholar
• BISOENDIAL RJ, HOVINGH GK, LEVELS JH et al.: Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation (2003) 107:2944-2948.
   PubMed Web of Science ®Google Scholar
• NISSEN SE, TSUNODA T, TUZCU EM: Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. J. Am. Med. Assoc. (2003) 290:2292-2300.
   PubMed Web of Science ®Google Scholar
• NISSEN SE, TUZCU EM, SCHOENHAGEN P et al.: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. J. Am. Med. Assoc. (2004) 291:1071-1080.
   PubMed Web of Science ®Google Scholar
• GLAGOV S, WEISENBERG E, ZARINS CK, STANKUNAVICIUS R, KOLETTIS GJ: Compensatory enlargement of human atherosclerotic coronary arteries. N. Engl. J. Med. (1987) 316:1371-1375.
   PubMed Web of Science ®Google Scholar
• NISSEN SE, TUZCU EM, SCHOENHAGEN P et al.: Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N. Engl. J. Med. (2005) 352:29-38.
   PubMed Web of Science ®Google Scholar
• INAZU A, BROWN ML, HESLER CB et al.: Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N. Engl. J. Med. (1990) 323:1234-1238.
   PubMed Web of Science ®Google Scholar
• GAYNOR BJ, SAND T, CLARK RW, AIELLO RJ, BAMBERGER MJ, MOBERLY JB: Inhibition of cholesteryl ester transfer protein activity in hamsters alters HDL lipid composition. Atherosclerosis (1994) 110:101-109.
   PubMed Web of Science ®Google Scholar
• BROUSSEAU ME, SCHAEFER EJ, WOLFE ML et al.: Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N. Engl. J. Med. (2004) 350:1505-1515.
   PubMed Web of Science ®Google Scholar
• BROUSSEAU ME, DIFFENDERFER MR, MILLER JS et al.: Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler. Thromb. Vasc. Biol. (2005) 25:1057-1064.
   PubMed Web of Science ®Google Scholar
• GRUNDY SM, BILHEIMER DW: Inhibition of 3-hydroxy-methylglutaryl-CoA reductase by mevinolin in familial hypercholesterolemia heterozygotes: effects on cholesterol balance. Proc. Natl. Acad. Sci. USA (1984) 81:2538-2542.
   PubMed Web of Science ®Google Scholar
• ZHANG Y, ZANOTTI I, REILLY MP, GLICK JM, ROTHBLAT GH, RADER DJ: Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation (2003) 108:661-663.
   Google Scholar
• PITT B, MANCINI GB, ELLIS SG, ROSMAN HS, PARK JS, McGOVERN ME: Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. J. Am. Coll. Cardiol. (1995) 26:1133-1139.
   PubMed Web of Science ®Google Scholar
• JUKEMA JW, BRUSCHKE AV, VAN BOVEN AJ et al.: Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation (1995) 91:2528-2540.
   PubMed Web of Science ®Google Scholar
• BYINGTON RP, FURBERG CD, CROUSE JR, ESPELAND MA, BOND MG: Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am. J. Cardiol. (1995) 76:54C-59C.
   PubMed Web of Science ®Google Scholar
• KRAGEL AH, REDDY SG, WITTES JT, ROBERTS WC: Morphometric analysis of the composition of coronary arterial plaques in isolated unstable angina pectoris with pain at rest. Am. J. Cardiol. (1990) 66:562-567.
   PubMed Web of Science ®Google Scholar
• DOLLAR AL, KRAGEL AH, FERNICOLA DJ, WACLAWIW MA, ROBERTS WC: Composition of atherosclerotic plaques in coronary arteries in women less than 40 years of age with fatal coronary artery disease and implications for plaque reversibility. Am. J. Cardiol. (1991) 67:1223-1227.
   PubMed Web of Science ®Google Scholar
• SIRTORI CR: ApoA-1Milano and regression of atherosclerosis. J. Am. Med. Assoc. (2004) 291:1319.
   Google Scholar
• SCHWARTZ GG, OLSSON AG, EZEKOWITZ MD et al.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. J. Am. Med. Assoc. (2001) 285:1711-1718.
   PubMed Web of Science ®Google Scholar
• McDONALD DL, TERRY TL, AGELLONG LB, NATION PN, FRANCIS GA: Administration of tyrosyl radical-oxidized HDL inhibits the development of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. (2003) 23:1583-1588.
   PubMed Web of Science ®Google Scholar